Clinical Management of Hemodialyzed Patients: From Pharmacological Interventions to Advanced Technologies
Funding
Conflicts of Interest
References
- Monardo, P.; Lacquaniti, A.; Campo, S.; Bucca, M.; Casuscelli di Tocco, T.; Rovito, S.; Ragusa, A.; Santoro, A. Updates on hemodialysis techniques with a common denominator: The personalization of the dialytic therapy. Semin. Dial. 2021, 34, 183–195. [Google Scholar] [CrossRef]
- Campo, S.; Lacquaniti, A.; Trombetta, D.; Smeriglio, A.; Monardo, P. Immune System Dysfunction and Inflammation in Hemodialysis Patients: Two Sides of the Same Coin. J. Clin. Med. 2022, 11, 3759. [Google Scholar] [CrossRef]
- Visconti, L.; Benvenga, S.; Lacquaniti, A.; Cernaro, V.; Bruzzese, A.; Conti, G.; Buemi, M.; Santoro, D. Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. J. Clin. Transl. Endocrinol. 2016, 6, 8–14. [Google Scholar] [CrossRef] [Green Version]
- Savica, V.; Santoro, D.; Monardo, P.; Mallamace, A.; Bellinghieri, G. Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. Ther. Clin. Risk Manag. 2008, 4, 821–826. [Google Scholar] [CrossRef] [Green Version]
- Zoccali, C.; Mallamaci, F.; Picano, E. Detecting and Treating Lung Congestion with Kidney Failure. Clin. J. Am. Soc. Nephrol. CJASN 2022, 17, 757–765. [Google Scholar] [CrossRef]
- Barbieri, C.; Cattinelli, I.; Neri, L.; Mari, F.; Ramos, R.; Brancaccio, D.; Canaud, B.; Stuard, S. Development of an artificial intelligence model to guide the management of blood pressure, fluid volume, and dialysis dose in end-stage kidney disease patients: Proof of concept and first clinical assessment. Kidney Dis. 2019, 5, 28–33. [Google Scholar] [CrossRef]
- Bolignano, D.; Coppolino, G.; Romeo, A.; Lacquaniti, A.; Buemi, M. Neutrophil gelatinase-associated lipocalin levels in chronic haemodialysis patients. Nephrology 2010, 15, 23–26. [Google Scholar] [CrossRef]
- Harrison, T.G.; Shukalek, C.B.; Hemmelgarn, B.R.; Zarnke, K.B.; Ronksley, P.E.; Iragorri, N.; Graham, M.M.; James, M.T. Association of NT-proBNP and BNP With Future Clinical Outcomes in Patients With ESKD: A Systematic Review and Meta-analysis. Am. J. Kidney Dis. 2020, 76, 233–247. [Google Scholar] [CrossRef]
- Loutradis, C.; Sarafidis, P.A.; Ferro, C.J.; Zoccali, C. Volume overload in hemodialysis: Diagnosis, cardiovascular consequences, and management. Nephrol. Dial. Transpl. 2021, 36, 2182–2193. [Google Scholar] [CrossRef]
- Lacquaniti, A.; Pasqualetti, P.; Casuscelli di Tocco, T.; Campo, S.; Rovito, S.; Bucca, M.; Ragusa, A.; Monardo, P. Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up. Kidney Res. Clin. Pract. 2020, 39, 334–343. [Google Scholar] [CrossRef]
- Singh, A.K.; Szczech, L.; Tang, K.L.; Barnhart, H.; Sapp, S.; Wolfson, M.; Reddan, D. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006, 355, 2085–2098. [Google Scholar] [CrossRef] [Green Version]
- Abdelazeem, B.; Abbas, K.S.; Shehata, J.; El-Shahat, N.A.; Baral, N.; Savarapu, P.; Kunadi, A. The efficacy of Roxadustat for the treatment of anemia in dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials. Ann. Transl. Med. 2021, 9, 1714. [Google Scholar] [CrossRef]
- Fishbane, S.; Pollock, C.A.; El-Shahawy, M.; Escudero, E.T.; Rastogi, A.; Van, B.P.; Frison, L.; Houser, M.; Pola, M.; Little, D.J.; et al. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study. J. Am. Soc. Nephrol. 2022, 33, 850–866. [Google Scholar] [CrossRef]
- Locatelli, F.; Del Vecchio, L. The Search for the Perfect Agent for Anemia Management in Chronic Kidney Disease. J. Am. Soc. Nephrol. 2022, 33, 662–664. [Google Scholar] [CrossRef]
- Guo, W.; Zhang, H.; Zhang, Y.; Huang, H.; Liu, W.; Diao, Z. Low Parathyroid Hormone Versus Secondary Hyperparathyroidism and Survival in Patients Undergoing Hemodialysis: A Propensity-Matched Analysis. Front. Endocrinol. 2022, 13, 869330. [Google Scholar] [CrossRef]
- Perrone, V.; Dovizio, M.; Veronesi, C.; Andretta, M.; Bartolini, F.; Cavaliere, A.; Ferrante, F.; Lupi, A.; Pagliaro, R.; Pagnotta, R. Real-World Evaluation of Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease, in an Italian Clinical Setting. Healthcare 2022, 10, 709. [Google Scholar] [CrossRef]
- D’Arrigo, G.; Mallamaci, F.; Pizzini, P.; Leonardis, D.; Tripepi, G.; Zoccali, C. CKD-MBD Biomarkers and CKD Progression: An Analysis by the Joint Model. Nephrol. Dial. Transpl. 2022, 36, gfac212. [Google Scholar] [CrossRef]
- Savica, V.; Calò, L.A.; Monardo, P.; Santoro, D.; Mallamace, A.; Muraca, U.; Bellinghieri, G. Salivary phosphorus and phosphate content of beverages: Implications for the treatment of uremic hyperphosphatemia. J. Ren. Nutr. 2009, 19, 69–72. [Google Scholar] [CrossRef] [Green Version]
- Ehlerding, G.; Ries, W.; Kempkes-Koch, M.; Ziegler, E.; Erlenkötter, A.; Zawada, A.M.; Kennedy, J.P.; Ottillinger, B.; Stauss-Grabo, M.; Lang, T. Randomized comparison of three high-flux dialyzers during high-volume online hemodiafiltration-the comPERFORM study. Clin. Kidney J. 2021, 15, 672–680. [Google Scholar] [CrossRef]
- Lin, C.L.; Yang, C.W.; Chiang, C.C.; Chang, C.T.; Huang, C.C. Long-term on-line hemodiafiltration reduces predialysis beta-2-microglobulin levels in chronic hemodialysis patients. Blood Purif. 2001, 19, 301–307. [Google Scholar] [CrossRef]
- Pedrini, L.A.; Comelli, M.; Ruggiero, P.; Feliciani, A.; Manfrini, V.; Cozzi, G.; Castellano, A.; Pezzotta, M.; Gatti, G.; Arazzi, M.; et al. Mixed hemodiafiltration reduces erythropoiesis stimulating agents requirement in dialysis patients: A prospective randomized study. J. Nephrol. 2020, 33, 1037–1048. [Google Scholar] [CrossRef] [PubMed]
- Guedes, M.; Vernooij, R.W.M.; Davenport, A.; Kuhlmann, M.K.; Aregger, F.; Pecoits-Filho, R. Clinical performance, intermediate and long-term outcomes of high-volume hemodiafiltration in patients with kidney failure. Semin. Dial. 2022. [Google Scholar] [CrossRef] [PubMed]
- Peters, S.; Bots, M.L.; Canaud, B.; Davenport, A.; Grooteman, M.P.; Kircelli, F.; Locatelli, F.; Maduell, F.; Morena, M.; Nubé, M.J.; et al. Haemodiafiltration and mortality in end-stage kidney disease patients: A pooled individual participant data analysis from four randomized controlled trials. Nephrol. Dial. Transpl. 2016, 31, 978–984. [Google Scholar] [CrossRef] [PubMed]
- Dellepiane, S.; Marengo, M.; D’Arezzo, M.; Donati, G.; Fabbrini, P.; Lacquaniti, A.; Ronco, C.; Cantaluppi, V. The Next Evolution of HemoDialysis eXpanded: From a Delphi Questionnaire-Based Approach to the Real Life of Italian Dialysis Units. Blood Purif. 2022, 1–10. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Monardo, P.; Lacquaniti, A. Clinical Management of Hemodialyzed Patients: From Pharmacological Interventions to Advanced Technologies. J. Clin. Med. 2022, 11, 4310. https://doi.org/10.3390/jcm11154310
Monardo P, Lacquaniti A. Clinical Management of Hemodialyzed Patients: From Pharmacological Interventions to Advanced Technologies. Journal of Clinical Medicine. 2022; 11(15):4310. https://doi.org/10.3390/jcm11154310
Chicago/Turabian StyleMonardo, Paolo, and Antonio Lacquaniti. 2022. "Clinical Management of Hemodialyzed Patients: From Pharmacological Interventions to Advanced Technologies" Journal of Clinical Medicine 11, no. 15: 4310. https://doi.org/10.3390/jcm11154310